Joincare Pharmaceutical Group Industry Co.,Ltd. (SHA:600380)
11.10
+0.22 (2.02%)
Apr 29, 2026, 3:00 PM CST
SHA:600380 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Net Income | 1,315 | 1,336 | 1,387 | 1,443 | 1,503 | 1,328 | Upgrade
|
| Depreciation & Amortization | 810.27 | 810.27 | 813.32 | 1,054 | 837.7 | 620.45 | Upgrade
|
| Other Amortization | 95.42 | 95.42 | 271.9 | 76.52 | 65.57 | 43.99 | Upgrade
|
| Loss (Gain) From Sale of Assets | 4.07 | 4.07 | -37.01 | 2.75 | 17.23 | -17.62 | Upgrade
|
| Asset Writedown & Restructuring Costs | 70.67 | 70.67 | 21.24 | 0.57 | 14.46 | 1.19 | Upgrade
|
| Loss (Gain) From Sale of Investments | -82.43 | -82.43 | -55.84 | -53.39 | 19.68 | -48.52 | Upgrade
|
| Provision & Write-off of Bad Debts | 1.27 | 1.27 | 4.38 | 17.09 | 2.98 | 9.19 | Upgrade
|
| Other Operating Activities | 1,886 | 1,760 | 1,761 | 1,812 | 1,543 | 1,446 | Upgrade
|
| Change in Accounts Receivable | -39.57 | -39.57 | 122.42 | 6,974 | 2,381 | -1,594 | Upgrade
|
| Change in Inventory | 357.42 | 357.42 | -51.29 | -415.39 | -604.73 | -306.33 | Upgrade
|
| Change in Accounts Payable | -282.14 | -282.14 | -493.78 | -7,047 | -1,925 | 1,037 | Upgrade
|
| Change in Other Net Operating Assets | - | - | -18.05 | 90.25 | 51.13 | 89.63 | Upgrade
|
| Operating Cash Flow | 3,997 | 3,892 | 3,636 | 3,929 | 3,978 | 2,563 | Upgrade
|
| Operating Cash Flow Growth | 15.04% | 7.03% | -7.45% | -1.23% | 55.19% | -15.27% | Upgrade
|
| Capital Expenditures | -751.9 | -767.2 | -979.13 | -1,130 | -1,148 | -1,521 | Upgrade
|
| Sale of Property, Plant & Equipment | 59.9 | 55.12 | 1.5 | 15.3 | 3.1 | 9.4 | Upgrade
|
| Cash Acquisitions | - | - | - | -22.46 | - | - | Upgrade
|
| Divestitures | 51.45 | - | -28.47 | - | - | 3.31 | Upgrade
|
| Investment in Securities | -2,152 | -1,332 | -169.38 | 130.21 | -1,230 | -580.79 | Upgrade
|
| Other Investing Activities | -1,830 | -1,824 | 21.47 | 129.67 | 122.15 | 125.34 | Upgrade
|
| Investing Cash Flow | -4,622 | -3,869 | -1,154 | -877.42 | -2,252 | -1,964 | Upgrade
|
| Long-Term Debt Issued | - | 4,182 | 6,637 | 4,274 | 5,340 | 3,535 | Upgrade
|
| Long-Term Debt Repaid | - | -5,307 | -7,309 | -3,831 | -3,752 | -2,621 | Upgrade
|
| Net Debt Issued (Repaid) | -1,444 | -1,125 | -672.08 | 442.75 | 1,588 | 913.44 | Upgrade
|
| Issuance of Common Stock | - | - | 96.56 | 38.12 | 701.08 | 82.58 | Upgrade
|
| Repurchase of Common Stock | -751.64 | -751.64 | -1,188 | -821.54 | -780.55 | -938.08 | Upgrade
|
| Common Dividends Paid | -447.24 | -447.07 | -468.15 | -480.86 | -389.04 | -382.47 | Upgrade
|
| Other Financing Activities | -435.53 | -622.52 | -804.11 | -1,106 | -553.15 | -650.36 | Upgrade
|
| Financing Cash Flow | -3,078 | -2,946 | -3,036 | -1,927 | 566.12 | -974.9 | Upgrade
|
| Foreign Exchange Rate Adjustments | -254.19 | -173.68 | 55.48 | 38.41 | 189.29 | -49.29 | Upgrade
|
| Net Cash Flow | -3,958 | -3,097 | -498.22 | 1,162 | 2,481 | -425.26 | Upgrade
|
| Free Cash Flow | 3,245 | 3,125 | 2,657 | 2,799 | 2,830 | 1,042 | Upgrade
|
| Free Cash Flow Growth | 26.95% | 17.59% | -5.06% | -1.10% | 171.67% | -52.53% | Upgrade
|
| Free Cash Flow Margin | 21.85% | 20.54% | 17.01% | 16.81% | 16.51% | 6.55% | Upgrade
|
| Free Cash Flow Per Share | 1.80 | 1.71 | 1.42 | 1.47 | 1.49 | 0.54 | Upgrade
|
| Cash Income Tax Paid | 1,570 | 1,670 | 1,865 | -54.22 | 103.82 | -0.08 | Upgrade
|
| Levered Free Cash Flow | 1,708 | 2,333 | 1,485 | 1,578 | 1,593 | 424.23 | Upgrade
|
| Unlevered Free Cash Flow | 1,762 | 2,388 | 1,562 | 1,670 | 1,680 | 480.65 | Upgrade
|
| Change in Working Capital | -103.23 | -103.23 | -529.32 | -423.56 | -25.24 | -820.13 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.